Literature DB >> 24395088

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

Augusto Villanueva1, Josep M Llovet2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395088     DOI: 10.1038/nrclinonc.2013.243

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

2.  Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling.

Authors:  Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

3.  Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

Authors:  Yujin Hoshida; Augusto Villanueva; Angelo Sangiovanni; Manel Sole; Chin Hur; Karin L Andersson; Raymond T Chung; Joshua Gould; Kensuke Kojima; Supriya Gupta; Bradley Taylor; Andrew Crenshaw; Stacey Gabriel; Beatriz Minguez; Massimo Iavarone; Scott L Friedman; Massimo Colombo; Josep M Llovet; Todd R Golub
Journal:  Gastroenterology       Date:  2013-01-17       Impact factor: 22.682

4.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

5.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

6.  Identification of driver genes in hepatocellular carcinoma by exome sequencing.

Authors:  Sean P Cleary; William R Jeck; Xiaobei Zhao; Kui Chen; Sara R Selitsky; Gleb L Savich; Ting-Xu Tan; Michael C Wu; Gad Getz; Michael S Lawrence; Joel S Parker; Jinyu Li; Scott Powers; Hyeja Kim; Sandra Fischer; Maha Guindi; Anand Ghanekar; Derek Y Chiang
Journal:  Hepatology       Date:  2013-09-24       Impact factor: 17.425

7.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

8.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.

Authors:  Jean Charles Nault; Maxime Mallet; Camilla Pilati; Julien Calderaro; Paulette Bioulac-Sage; Christophe Laurent; Alexis Laurent; Daniel Cherqui; Charles Balabaud; Jessica Zucman-Rossi; Jessica Zucman Rossi
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.

Authors:  Zhengyan Kan; Hancheng Zheng; Xiao Liu; Shuyu Li; Thomas D Barber; Zhuolin Gong; Huan Gao; Ke Hao; Melinda D Willard; Jiangchun Xu; Robert Hauptschein; Paul A Rejto; Julio Fernandez; Guan Wang; Qinghui Zhang; Bo Wang; Ronghua Chen; Jian Wang; Nikki P Lee; Wei Zhou; Zhao Lin; Zhiyu Peng; Kang Yi; Shengpei Chen; Lin Li; Xiaomei Fan; Jie Yang; Rui Ye; Jia Ju; Kai Wang; Heather Estrella; Shibing Deng; Ping Wei; Ming Qiu; Isabella H Wulur; Jiangang Liu; Mariam E Ehsani; Chunsheng Zhang; Andrey Loboda; Wing Kin Sung; Amit Aggarwal; Ronnie T Poon; Sheung Tat Fan; Jun Wang; James Hardwick; Christoph Reinhard; Hongyue Dai; Yingrui Li; John M Luk; Mao Mao
Journal:  Genome Res       Date:  2013-06-20       Impact factor: 9.043

  10 in total
  58 in total

1.  TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma.

Authors:  Daniel Wai-Hung Ho; Alan Ka-Lun Kai; Irene Oi-Lin Ng
Journal:  Front Med       Date:  2015-08-14       Impact factor: 4.592

2.  Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.

Authors:  Lei Li; Li Che; Kevin M Tharp; Hyo-Min Park; Maria G Pilo; Dan Cao; Antonio Cigliano; Gavinella Latte; Zhong Xu; Silvia Ribback; Frank Dombrowski; Matthias Evert; Gregory J Gores; Andreas Stahl; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

Review 3.  Hepatocellular carcinoma.

Authors:  Marie-Annick Buendia; Christine Neuveut
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

Review 4.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

5.  RETRACTED ARTICLE: Circular RNA ABCB10 promotes hepatocellular carcinoma progression by increasing HMG20A expression by sponging miR-670-3p.

Authors:  Yu Fu; Limin Cai; Xuexue Lei; Dunwei Wang
Journal:  Cancer Cell Int       Date:  2019-12-16       Impact factor: 5.722

6.  Oncogene UBE2I enhances cellular invasion, migration and proliferation abilities via autophagy-related pathway resulting in poor prognosis in hepatocellular carcinoma.

Authors:  Xiang-Kun Wang; Xi-Wen Liao; Xin Zhou; Chuang-Ye Han; Zi-Jun Chen; Cheng-Kun Yang; Jian-Lu Huang; Jian-Yao Wang; Jun-Qi Liu; Hua-Sheng Huang; Shu-Tian Mo; Xin-Ping Ye; Guang-Zhi Zhu; Tao Peng
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 7.  Liver cancer: Approaching a personalized care.

Authors:  Jordi Bruix; Kwang-Hyub Han; Gregory Gores; Josep Maria Llovet; Vincenzo Mazzaferro
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

8.  Liver cancer: time to evolve trial design after everolimus failure.

Authors:  Josep M Llovet
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

Review 9.  Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2.

Authors:  Michael Karin; Debanjan Dhar
Journal:  Carcinogenesis       Date:  2016-05-04       Impact factor: 4.944

10.  HBx/ERα complex-mediated LINC01352 downregulation promotes HBV-related hepatocellular carcinoma via the miR-135b-APC axis.

Authors:  Pinbo Huang; Qiaodong Xu; Yongcong Yan; Yingjuan Lu; Zhigang Hu; Bing Ou; Heyun Zhang; Kai Mao; Jianlong Zhang; Jie Wang; Zhiyu Xiao
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.